BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21447712)

  • 1. Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma.
    Abraham J; Prajapati SI; Nishijo K; Schaffer BS; Taniguchi E; Kilcoyne A; McCleish AT; Nelon LD; Giles FG; Efstratiadis A; LeGallo RD; Nowak BM; Rubin BP; Malempati S; Keller C
    Mol Cancer Ther; 2011 Apr; 10(4):697-707. PubMed ID: 21447712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma.
    Zumsteg A; Caviezel C; Pisarsky L; Strittmatter K; García-Echeverría C; Hofmann F; Christofori G
    Mol Cancer Res; 2012 Jun; 10(6):800-9. PubMed ID: 22562956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
    Browne BC; Eustace AJ; Kennedy S; O'Brien NA; Pedersen K; McDermott MS; Larkin A; Ballot J; Mahgoub T; Sclafani F; Madden S; Kennedy J; Duffy MJ; Crown J; O'Donovan N
    Breast Cancer Res Treat; 2012 Dec; 136(3):717-27. PubMed ID: 23117852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line.
    Ekyalongo RC; Mukohara T; Kataoka Y; Funakoshi Y; Tomioka H; Kiyota N; Fujiwara Y; Minami H
    Invest New Drugs; 2013 Apr; 31(2):293-303. PubMed ID: 22828916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.
    Bielen A; Perryman L; Box GM; Valenti M; de Haven Brandon A; Martins V; Jury A; Popov S; Gowan S; Jeay S; Raynaud FI; Hofmann F; Hargrave D; Eccles SA; Jones C
    Mol Cancer Ther; 2011 Aug; 10(8):1407-18. PubMed ID: 21659463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K; Hamacher A; Engelke LH; Kassack MU
    BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
    Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
    Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
    Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
    Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
    Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.
    Tarn C; Rink L; Merkel E; Flieder D; Pathak H; Koumbi D; Testa JR; Eisenberg B; von Mehren M; Godwin AK
    Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8387-92. PubMed ID: 18550829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Picropodophyllin (PPP) is a potent rhabdomyosarcoma growth inhibitor both in vitro and in vivo.
    Tarnowski M; Tkacz M; Zgutka K; Bujak J; Kopytko P; Pawlik A
    BMC Cancer; 2017 Aug; 17(1):532. PubMed ID: 28793874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.
    Browne BC; Crown J; Venkatesan N; Duffy MJ; Clynes M; Slamon D; O'Donovan N
    Ann Oncol; 2011 Jan; 22(1):68-73. PubMed ID: 20647220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
    Höpfner M; Baradari V; Huether A; Schöfl C; Scherübl H
    Endocr Relat Cancer; 2006 Mar; 13(1):135-49. PubMed ID: 16601284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.
    Ioannou N; Seddon AM; Dalgleish A; Mackintosh D; Modjtahedi H
    BMC Cancer; 2013 Jan; 13():41. PubMed ID: 23367880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
    Wolf S; Lorenz J; Mössner J; Wiedmann M
    World J Gastroenterol; 2010 Jan; 16(2):156-66. PubMed ID: 20066734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma.
    Kang Z; Yu Y; Zhu YJ; Davis S; Walker R; Meltzer PS; Helman LJ; Cao L
    Oncogene; 2014 Dec; 33(50):5697-705. PubMed ID: 24292683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541.
    Hägerstrand D; Lindh MB; Peña C; Garcia-Echeverria C; Nistér M; Hofmann F; Ostman A
    Neuro Oncol; 2010 Sep; 12(9):967-75. PubMed ID: 20378689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
    Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
    PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.